Literature DB >> 1981682

Prevention of sudden death by beta-blockade.

N Rehnqvist1.   

Abstract

Beta-adrenoreceptor blocking agents have been used to relieve symptoms mainly in patients with ischemic heart disease. Prophylactic use of beta blockade in patients after acute myocardial infarction has shown a reduction in total mortality and also in sudden death. The overall total mortality reduction amounts to about 30%, whereas the reduction in the sudden death rate is 50%. The mechanisms behind this reduction in sudden death are probably manifold. Antiarrhythmic effects in ischemic myocardium, prevention of new ischemia, and also perhaps other factors may play a role. Apart from the prevention effect in chronic ischemic heart disease, beta blockers have also been able to reduce the sudden death rate in the long QT syndrome and are suggested for use in congestive cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1981682     DOI: 10.1007/bf01856554

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  20 in total

Review 1.  Secondary prevention after myocardial infarction: a review of long-term trials.

Authors:  G S May; K A Eberlein; C D Furberg; E R Passamani; D L DeMets
Journal:  Prog Cardiovasc Dis       Date:  1982 Jan-Feb       Impact factor: 8.194

Review 2.  By what means might beta blockers prolong life after acute myocardial infarction?

Authors:  J D Fitzgerald
Journal:  Eur Heart J       Date:  1987-09       Impact factor: 29.983

3.  Beta-adrenoceptor blockade, platelets, and rheologic factors.

Authors:  K Winther; C Hedman
Journal:  Cephalalgia       Date:  1986       Impact factor: 6.292

4.  Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade.

Authors:  K Swedberg; A Hjalmarson; F Waagstein; I Wallentin
Journal:  Lancet       Date:  1979-06-30       Impact factor: 79.321

5.  Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy.

Authors:  F Waagstein; A Hjalmarson; E Varnauskas; I Wallentin
Journal:  Br Heart J       Date:  1975-10

6.  Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol.

Authors:  R M Norris; P F Barnaby; M A Brown; G G Geary; E D Clarke; R L Logan; D N Sharpe
Journal:  Lancet       Date:  1984-10-20       Impact factor: 79.321

7.  Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease.

Authors:  B O Olofsson; G Dahlén; T K Nilsson
Journal:  Eur Heart J       Date:  1989-01       Impact factor: 29.983

8.  The long QT syndrome: a prospective international study.

Authors:  A J Moss; P J Schwartz; R S Crampton; E Locati; E Carleen
Journal:  Circulation       Date:  1985-01       Impact factor: 29.690

9.  Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity.

Authors:  G Olsson; N Rehnqvist; A Sjögren; L Erhardt; T Lundman
Journal:  J Am Coll Cardiol       Date:  1985-06       Impact factor: 24.094

10.  A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results.

Authors: 
Journal:  JAMA       Date:  1982-03-26       Impact factor: 56.272

View more
  3 in total

Review 1.  Should calcium antagonists be used after myocardial infarction? Ischemia selectivity versus vascular selectivity.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1992-02       Impact factor: 3.727

Review 2.  Calcium antagonists post-infarction: the significance of experimental studies on potentially lethal early ischemic ventricular arrhythmias.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

3.  Attenuation of the ischaemia-induced fall of electrical ventricular fibrillation threshold by a calcium antagonist, diltiazem.

Authors:  J F Aupetit; Q Timour; G Chevrel; J Loufoua-Moundanga; S Omar; G Faucon
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-11       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.